Follow us
PRO-NEM1
Diagnostic value to discriminate MEN1 Patients With or Without Neuroendocrine Tumors
MEN1 (Multiple Endocrine Neoplasia type 1) is a genetic disorder that predisposes individuals to develop tumors in various endocrine glands, including the pancreas, parathyroid, and pituitary glands. One of the significant concerns for individuals with MEN1 is the development of neuroendocrine tumors (NETs), which can occur in multiple organs. MEN1 patients currently undergo regular biological and morphological screening, at least annually, in order to screen the development of NETs. However, despite these diagnostic tools, there are still unmet needs in effectively diagnosing NETs in this population who has a high risk of developing cancer.
The study will enroll 297 patients with multiple encocrine neoplasia type 1 (MEN1) with or without neuroendocrine tumors. Blood samples will be taken in both patients to evaluate plasma concentrations of hPG80.
Study in partnership with the CHU Dijon (France).
PRO-NEM1 is registered at ClinicalTrials.gov (NCT06430021)
Current Status: Enrolling